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239 Table S1. The optimized MS parameters to measure amino acids in this study.
Amino Acid Precursor Ion Product Ion CE Fragmentor Accelerator voltage
isoleucine/leucinea 132.1 86.1 10 80 1
valine 118.2 72.2 10 80 1
glutamineb 147.1 83.8 20 80 1
glutamic acid 148.0 84.2 15 80 1
tryptophan 205.1 118.0 25 80 5
proline 116.1 70.2 15 80 1
threonine 120.1 74.2 10 80 1
histidine 156.1 110.0 10 80 5
alanine 90.1 43.9 10 60 1
serine 105.9 60.1 10 60 1
aspartic acid 133.9 74.0 15 80 1
tyrosine 182.1 136.1 10 80 3
methionine 150.0 104.1 10 80 1
cysteinec 121.8 75.9 15 140 1
lysineb 147.0 84.1 15 80 7
phenylalanine 166.1 120.1 10 80 5
arginine 175.1 70.2 25 80 1
asparagine 132.9 74.0 15 80 1
glycine 76.2 29.9 10 60 1
40
41 aIsoleucine and leucine have the same optimized MS parameters.
42 bGlutamine and lysine have different but very similar optimized MS parameters. In this study, 
43 they were measured separately, but they were combined for data analysis.
44 cWe could not obtain a good sensitivity or peak shape for cysteine; therefore, it was excluded 
45 from analysis in this study. 
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49 Fig. S1. The characterization of Myc-On and Myc-Off cells. a) Western blot showing that 
50 Tet21N cells can express a doxycycline-repressible N-Myc construct which allows for inducible 
51 N-Myc expression in the presence/absence of doxycycline (Myc-Off/Myc-On), b) ectopic N-Myc 
52 induces hyperproliferation, and c) N-Myc induces anchorage-independent growth in soft agar, 
53 an indicator of malignant transformation.
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56 Fig. S2. Box-and-whisker plots for the amino acid markers in constructing the model in Fig. 5d.: 
57 a) aspartic acid, glutamic acid, glutamine/lysine, and histidine from FAAs, b) lysine from 
58 FSPAAs, and c) arginine, serine, and tyrosine from IPAAs. 
59
560 Separate Excel File: The integrated areas and BCA values for cell and serum samples. 
